Literature DB >> 23398790

Reaching targets for mineral metabolism clinical practice guidelines and its impact on outcomes among Mexican chronic dialysis patients.

Ramón Paniagua1, María-de-Jesús Ventura, Marcela Ávila-Díaz, Héctor Hinojosa-Heredia, Antonio Méndez-Duran, Alejandra Cisneros, Ana María Gómez, Alfonso Cueto-Manzano, Pedro Trinidad, Gregorio T Obrador, Elvia García-López, Bengt Lindholm.   

Abstract

BACKGROUND AND AIMS: An increasing number of studies have been published concerning meeting targets of clinical guidelines for different aspects of the diagnosis and treatment of patients with end-stage renal disease. Most of these studies have shown that guideline recommendations are not always satisfied, and results outside target limits have been associated with high rates of mortality and morbidity. The objective of this study was to analyze the frequency of reaching mineral and bone metabolism-related guideline targets and its impact on clinical outcomes in Mexican chronic dialysis patients.
METHODS: A cohort of prevalent peritoneal dialysis (PD) and hemodialysis (HD) patients were analyzed at baseline and followed for at least 16 months. Patients were on continuous ambulatory peritoneal dialysis (CAPD), automated peritoneal dialysis (APD), and HD and contracted HD modalities where patients received HD sessions outside institution facilities.
RESULTS: We studied 753 patients. The percentage of patients within target limits for phosphorus was 35%, for calcium 32%, and for PTH 12%. The most frequent pattern was hyperphosphatamia, hypercalcemia, and low PTH. This was even more frequent in CAPD patients, probably due to the high percentage of diabetic patients. Hypercalcemia was found as an independent risk factor for mortality.
CONCLUSIONS: The most important results suggest that guideline recommendations are not usually satisfied and that hypercalcemia, in addition to other traditional risk factors, is associated with high mortality rates. The study also detected some opportunities to improve the quality of treatment by reducing the calcium content of dialysis solutions and reducing the use of calcium carbonate as a phosphate binder.
Copyright © 2013 IMSS. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23398790     DOI: 10.1016/j.arcmed.2013.01.008

Source DB:  PubMed          Journal:  Arch Med Res        ISSN: 0188-4409            Impact factor:   2.235


  3 in total

1.  Dietary phosphorus intake and distribution in Chinese peritoneal dialysis patients with and without hyperphosphatemia.

Authors:  Na Jiang; Wei Fang; Xiaoxiao Yang; Lin Zhang; Jiangzi Yuan; Aiwu Lin; Zhaohui Ni; Jiaqi Qian
Journal:  Clin Exp Nephrol       Date:  2014-09-05       Impact factor: 2.801

2.  Osteoprotegerin Is a Better Predictor for Cardiovascular and All-Cause Mortality than Vascular Calcifications in a Multicenter Cohort of Patients on Peritoneal Dialysis.

Authors:  Marcela Ávila; Ma Del Carmen Prado; Renata Romero; Ricardo Córdova; Ma Del Carmen Rigo; Miguel Trejo; Carmen Mora; Ramón Paniagua
Journal:  Biomolecules       Date:  2022-04-08

3.  Randomized Trial of Acute Changes in Plasma Phosphate After Phosphorus-Standardized Meals in Peritoneal Dialysis.

Authors:  Martin Thorbjørn Lundin; Iain Bressendorff; Bent Kristensen; Niklas Rye Jørgensen; Rizwan Butt; Ditte Hansen
Journal:  Kidney Int Rep       Date:  2021-01-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.